Implementing the National Heart, Lung, and Blood Institute’s Strategic Vision in the Division of Cardiovascular Sciences (original) (raw)
Related papers
Health Innovation in cardiovascular disease SM liew et al AMJ 06 67 1 2013
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. Despite efforts to tackle CVD, its prevalence continues to escalate in almost every country. The problem requires an exploration of novel ways to uncover solutions. Health innovations that embrace new knowledge and technology possess the potential to revolutionize the management of CVD. Using findings from published studies on CVD, researchers generated innovations in the areas of global risk assessment, home and remote monitoring and bedside testing. The use of pharmacogenetics and methods to support lifestyle changes represent other potential topics for innovations. Gaps in existing knowledge and practice of CVD provide opportunities for the development of new ideas, practices and technology. However, healthcare professionals need to be cognisant of the limitations of health innovations and advocate for safeguarding patients' wellbeing.
iScience
In this backstory, researchers from Swiss Federal Institute of Technology (ETH Zurich) who initiated an interdisciplinary program to generate innovative solutions for different cardiovascular diseases, such as myocardial infarction, valvular replacement, and movement-based rehabilitation therapy, discuss the benefits and challenges of interdisciplinary research. Cardiovascular disease (CVD) is the leading cause of terminal illness worldwide. Aging population, improper nutrition, and sedentary but stressful lifestyle combined with poor prevention, malignant infections, and high risk-factors (like smoking and obesity) render CVD a leading threat to human health. Lifelong treatment, diminished quality of life, repeated hospitalizations, and only short periods of stable health, mark the lives of patients suffering from CVD. In front of this challenge, the Swiss Federal Institute of Technology (ETH Zurich) initiated an interdisciplinary program to generate innovative solutions for different CVDs, such as myocardial infarction, valvular replacement, and movement-based rehabilitation therapy.
Circulation, 2020
Each decade, the American Heart Association (AHA) develops an Impact Goal to guide its overall strategic direction and investments in its research, quality improvement, advocacy, and public health programs. Guided by the AHA’s new Mission Statement, to be a relentless force for a world of longer, healthier lives, the 2030 Impact Goal is anchored in an understanding that to achieve cardiovascular health for all, the AHA must include a broader vision of health and well-being and emphasize health equity. In the next decade, by 2030, the AHA will strive to equitably increase healthy life expectancy beyond current projections, with global and local collaborators, from 66 years of age to at least 68 years of age across the United States and from 64 years of age to at least 67 years of age worldwide. The AHA commits to developing additional targets for equity and well-being to accompany this overarching Impact Goal. To attain the 2030 Impact Goal, we recommend a thoughtful evaluation of in...
2011
Paul A. Heidenreich, MD, MS, FAHA, Chair; Justin G. Trogdon, PhD; Olga A. Khavjou, MA; Javed Butler, MD, MPH, FAHA; Kathleen Dracup, RN, DNSc; Michael D. Ezekowitz, MBChB, DPhil, FRCP, FAHA; Eric Andrew Finkelstein, PhD, MHA; Yuling Hong, MD, PhD, FAHA*; S. Claiborne Johnston, MD, PhD, FAHA; Amit Khera, MD, MSc; Donald M. Lloyd-Jones, MD, MSc, FAHA; Sue A. Nelson, MPA; Graham Nichol, MD, MPH, FRCP(C), FAHA; Diane Orenstein, PhD*; Peter W.F. Wilson, MD, FAHA; Y. Joseph Woo, MD, FAHA; on behalf of the American Heart Association Advocacy Coordinating Committee, Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease, Council on Cardiovascular Surgery and Anesthesia, and Interdisciplin...
Circulation, 2011
Forecasting the Future of Cardiovascular Disease in the United States: A Policy http://circ.ahajournals.org located on the World Wide Web at: The online version of this article, along with updated information and services, is http://www.lww.com/reprints Reprints: Information about reprints can be found online at Background-Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results-To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from 273billionto273 billion to 273billionto818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from 172billionin2010to172 billion in 2010 to 172billionin2010to276 billion in 2030, an increase of 61%. Conclusions-These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD. (Circulation. 2011;123:00-00.)